TheraRadar
Data updated: May 26, 2026

TOPICORT (desoximetasone)

Corticosteroid Hormone Receptor Agonists
Dermatology Approved 1977-02-28

Topicort (desoximetasone ointment USP) 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

10
Indications
--
Phase 3 Trials
49
Years on Market

Details

Status
Prescription
First Approved
1977-02-28
Patent Cliff
2028

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
TOPICAL
Dosage Forms
OINTMENT, CREAM, GEL, SPRAY

Companies

Active Ingredient: DESOXIMETASONE

TOPICORT Approval History

1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
106 FDA actions from 1977 to 2021 · 1 indication expansions
Oct 2021 SUPPL
Efficacy
Dec 2015 SUPPL
Label · Labeling
Nov 2015 SUPPL
Mfg · Manufacturing (CMC)

What TOPICORT Treats

10 FDA approvals

Originally approved for its first indication in 1977 . Covers 10 distinct patient populations.

  • Other (10)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TOPICORT FDA Label Details

Indications & Usage

FDA Label (PDF)

Topicort ® (desoximetasone ointment USP) 0.05% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

View full patent landscape →
2 OB patents · 1 families · 12 international docs across 5 countries

TOPICORT Patents & Exclusivity

Latest Patent: Sep 2028

Patents (2 active)

US8277780 Expires Sep 1, 2028
US8715624 Expires May 26, 2026
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for TOPICORT

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2028
  • 2 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.